文献速递外周动脉疾病

药物涂层球囊与普通球囊治疗股腘动脉病变的系统综述与更新荟萃分析

Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
PubMed 文献 · J Vasc Surg · 2019-05-21

该系统综述与荟萃分析纳入13项随机对照试验、6个全球注册研究和3个长病变全球注册研究,均使用紫杉醇药物涂层球囊(DCB)。2年时DCB在靶病变血运重建、一期通畅率、晚期管腔丢失方面显著优于普通球囊(POBA),但截肢率和踝肱指数变化无显著差异。亚组分析显示男性、标准剂量DCB及尿素赋形剂效果更优,而糖尿病、严重钙化及腘动脉病变效果较差。

要点

  • DCB在股腘动脉病变中2年靶病变血运重建和一期通畅率显著优于POBA。
  • 糖尿病、严重钙化及腘动脉病变使用DCB效果较差,男性患者效果更优。
  • 标准剂量(3 μg/mm2)DCB较低剂量(2 μg/mm2)更有效减少再狭窄。

核心结论

  • DCB血管成形术是治疗股腘动脉疾病的有效方法,具有高手术成功率,在行业赞助试验的荟萃分析中一致减少晚期管腔丢失、再狭窄和靶病变血运重建。
  • 需要进一步独立的非行业赞助随机对照试验来明确DCB在膝下闭塞性疾病治疗中的作用。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Embase、Cochrane对照试验中心注册库、ClinicalTrials.gov及国际会议记录。
  • 纳入13项随机对照试验、6个全球注册研究和3个关注长病变的全球注册研究,DCB组均使用紫杉醇。

主要发现

  • 2年时DCB组靶病变血运重建显著优于POBA(OR 0.29;95%CI 0.20-0.40)。
  • 2年时DCB组一期通畅率显著优于POBA(OR 0.38;95%CI 0.27-0.54)。
  • 2年时DCB组晚期管腔丢失显著优于POBA(平均直径差-0.80 mm;95%CI -1.44至-0.16)。
  • 2年时DCB组与POBA组在Rutherford分级上无显著差异(OR 0.82;95%CI 0.57-1.19)。
  • DCB与POBA在截肢或踝肱指数变化方面无显著差异。

关键数值与推荐

  • 亚组分析:男性患者DCB效果显著优于女性;糖尿病、严重钙化病变、腘动脉病变效果显著差于非糖尿病、非钙化/轻中度钙化、单纯股浅动脉病变。
  • 标准剂量(3 μg/mm2)DCB在减少再狭窄方面显著优于低剂量(2 μg/mm2)DCB。
  • 低剂量DCB中,聚乙二醇赋形剂显著优于聚山梨酯和山梨醇;标准剂量DCB的尿素赋形剂再狭窄显著少于低剂量DCB的聚山梨酯和山梨醇赋形剂。
  • 二次支架置入和非预扩张病变效果未显著变差。

临床怎么用

  • 对于股腘动脉闭塞性疾病,DCB可考虑作为减少再狭窄和靶病变血运重建的治疗选择。
  • 在糖尿病、严重钙化或腘动脉病变患者中,需权衡DCB的预期效果。
  • 选择DCB时,标准剂量(3 μg/mm2)可能较低剂量(2 μg/mm2)更有效。

局限性

  • 试验间存在异质性,支架置入频率和双联抗血小板治疗持续时间不同。
  • 纳入的试验多为行业赞助,需要独立的非行业赞助随机对照试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: An endovascular-first approach is usually recommended in femoropopliteal occlusive disease. However, despite high technical success, plain old balloon angioplasty (POBA) is burdened with high restenosis rates. To reduce this phenomenon, local delivery of drugs has been proposed by way of drug-coated balloons (DCBs). Our goal was to review the evidence for the use of DCBs in the management of femoropopliteal disease and to determine whether it is associated with improved outcomes compared with POBA. METHODS: Electronic searches of PubMed (MEDLINE), Embase, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and proceedings of international conferences were performed to identify randomized controlled trials (RCTs) and observational registries evaluating the use of DCBs for femoropopliteal arterial occlusive disease. RESULTS: This meta-analysis included 13 RCTs, 6 global registries, and 3 global registries focusing on long lesions. They all used paclitaxel in the DCB arm. There was heterogeneity between trials, and the frequency of stent deployment and duration of dual antiplatelet therapy differed. At 2 years, there were significantly better outcomes for DCBs in terms of target lesion revascularization (odds ratio [OR], 0.29; 95% confidence interval [CI], 0.20-0.40), primary patency (OR, 0.38; 95% CI, 0.27-0.54), late lumen loss (mean diameter, -0.80 mm; 95% CI, -1.44 to -0.16), and Rutherford category (OR, 0.82; 95% CI, 0.57-1.19). There was no significant difference between DCBs and POBA in amputation or change in ankle-brachial index. A subgroup analysis revealed that male patients treated with DCBs performed significantly better than female patients and that diabetics, heavily calcified lesions, and popliteal lesions performed significantly worse than nondiabetics, noncalcified and mild to moderately calcified lesions, and exclusive superficial femoral artery lesions, respectively. Secondarily stented and nonpredilated lesions did not perform significantly worse, but standard-dose (3 μg/mm2) DCBs were significantly more effective than low-dose (2 μg/mm2) DCBs in reducing binary restenosis. In addition, in a low-dose DCB, the polyethylene glycol excipient performed significantly better than polysorbate and sorbitol, whereas binary restenosis was significantly less frequent with the urea excipient, associated with a standard-dose DCB, compared with the polysorbate and sorbitol excipient, associated with a low-dose DCB. CONCLUSIONS: DCB angioplasty is an effective treatment associated with high procedural success. In a meta-analysis of industry-sponsored trials, it consistently reduced late lumen loss, binary restenosis, and target lesion revascularization compared with POBA alone in the treatment of femoropopliteal disease. Further independent, non-industry-sponsored RCTs are necessary to better delineate the role of DCBs in the treatment of infrainguinal occlusive disease.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Caradu C, Lakhlifi E, Colacchio EC, et al. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease. J Vasc Surg. 2019. PMID: 31126769. doi:10.1016/j.jvs.2019.01.080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。